174 related articles for article (PubMed ID: 20490651)
1. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Yan M; Rayoo M; Takano EA; ; Fox SB
Breast Cancer Res Treat; 2011 Apr; 126(2):395-405. PubMed ID: 20490651
[TBL] [Abstract][Full Text] [Related]
2. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
Shaaban AM; Green AR; Karthik S; Alizadeh Y; Hughes TA; Harkins L; Ellis IO; Robertson JF; Paish EC; Saunders PT; Groome NP; Speirs V
Clin Cancer Res; 2008 Aug; 14(16):5228-35. PubMed ID: 18698041
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma.
Chantzi NI; Tiniakos DG; Palaiologou M; Goutas N; Filippidis T; Vassilaros SD; Dhimolea E; Mitsiou DJ; Alexis MN
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1489-98. PubMed ID: 23817696
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptors β1 and β2 are associated with distinct responses of estrogen receptor α-positive breast carcinoma to adjuvant endocrine therapy.
Dhimolea E; Tiniakos DG; Chantzi ΝΙ; Goutas N; Vassilaros SD; Mitsiou DJ; Alexis ΜN
Cancer Lett; 2015 Mar; 358(1):37-42. PubMed ID: 25524554
[TBL] [Abstract][Full Text] [Related]
5. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.
Vinayagam R; Sibson DR; Holcombe C; Aachi V; Davies MP
BMC Cancer; 2007 Jul; 7():131. PubMed ID: 17640362
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer.
Ciucci A; Zannoni GF; Travaglia D; Petrillo M; Scambia G; Gallo D
Gynecol Oncol; 2014 Feb; 132(2):351-9. PubMed ID: 24378878
[TBL] [Abstract][Full Text] [Related]
7. Different associations of estrogen receptor β isoforms, ERβ1 and ERβ2, expression levels with tumor size and survival in early- and late-onset breast cancer.
Mandusic V; Dimitrijevic B; Nikolic-Vukosavljevic D; Neskovic-Konstantinovic Z; Kanjer K; Hamann U
Cancer Lett; 2012 Aug; 321(1):73-9. PubMed ID: 22366496
[TBL] [Abstract][Full Text] [Related]
8. ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid.
Meligova AK; Siakouli D; Stasinopoulou S; Xenopoulou DS; Zoumpouli M; Ganou V; Gkotsi EF; Chatziioannou A; Papadodima O; Pilalis E; Alexis MN; Mitsiou DJ
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835157
[TBL] [Abstract][Full Text] [Related]
9. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
Wurster M; Ruoff A; Meisner C; Seeger H; Vogel U; Juhasz-Böss I; Solomayer E; Wallwiener D; Fehm T; Neubauer H
Oncol Rep; 2010 Sep; 24(3):653-9. PubMed ID: 20664970
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
Speirs V; Viale G; Mousa K; Palmieri C; Reed SN; Nicholas H; Cheang M; Jassem J; Lønning PE; Kalaitzaki E; van de Velde CJH; Rasmussen BB; Verhoeven DM; Shaaban AM; Bartlett JMS; Bliss JM; Coombes RC;
Ann Oncol; 2015 Sep; 26(9):1890-1897. PubMed ID: 26002610
[TBL] [Abstract][Full Text] [Related]
12. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR
BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324
[TBL] [Abstract][Full Text] [Related]
13. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
Yan S; Dey P; Ziegler Y; Jiao X; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Breast Cancer Res Treat; 2021 Jan; 185(2):281-292. PubMed ID: 33001337
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer Expression Profiles of Cytoplasmic ERβ1 and Nuclear ERβ2 are Associated with Poor Outcomes following Radical Prostatectomy.
Schade GR; Holt SK; Zhang X; Song D; Wright JL; Zhao S; Kolb S; Lam HM; Levin L; Leung YK; Ho SM; Stanford JL
J Urol; 2016 Jun; 195(6):1760-6. PubMed ID: 26804755
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
Chan KKL; Siu MKY; Jiang YX; Wang JJ; Wang Y; Leung THY; Liu SS; Cheung ANY; Ngan HYS
BMC Cancer; 2017 Aug; 17(1):606. PubMed ID: 28859612
[TBL] [Abstract][Full Text] [Related]
17. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer.
Davies MP; O'Neill PA; Innes H; Sibson DR; Prime W; Holcombe C; Foster CS
J Mol Endocrinol; 2004 Dec; 33(3):773-82. PubMed ID: 15591034
[TBL] [Abstract][Full Text] [Related]
18. The expression of estrogen receptors β2, 5 identifies and is associated with prognosis in non-small cell lung cancer.
Liu Z; Liao Y; Tang H; Chen G
Endocrine; 2013 Oct; 44(2):517-24. PubMed ID: 23475473
[TBL] [Abstract][Full Text] [Related]
19. Differential expression patterns of estrogen receptor (ER)-β splice variants between papillary thyroid cancer and nodular thyroid goiter.
Dong W; Li J; Huang Y; Zhang H; Shan Z; Teng W
Med Sci Monit; 2012 Sep; 18(9):BR351-5. PubMed ID: 22936184
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.
Leung YK; Lam HM; Wu S; Song D; Levin L; Cheng L; Wu CL; Ho SM
Endocr Relat Cancer; 2010 Sep; 17(3):675-89. PubMed ID: 20501637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
